Effectiveness of GLP-1 Agonists in Managing Alcohol Use Disorder
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 6th, 2025
|
GLP-1 agonists, including semaglutide and liraglutide, have proven effective in managing diabetes and obesity. Additionally, biological research has suggested that activating the GLP-1 receptor may help reduce alcohol consumption. A study recently published in the Journal of the American Medical Association explored the potential of using GLP-1 agonists like semaglutide and liraglutide to treat alcohol use disorder.
The retrospective cohort study analyzed over two hundred thousand medical records from the Swedish National Patient Registry, collected between 2006 and 2023. The study included participants aged 16 to 64 who had been diagnosed with alcohol use disorder. Over 6,000 participants were using GLP-1 agonists, with the majority taking semaglutide, and smaller proportions using liraglutide, dulaglutide, and exenatide. With a median follow-up of approximately 9 years, the researchers found that semaglutide and liraglutide significantly reduced the risk of hospitalization due to alcohol use disorder by 36% and 28%, respectively. Furthermore, the study indicated that these GLP-1 agonists were more effective than specialized medications such as naltrexone, disulfiram, and acamprosate. However, due to the study's design, the researchers emphasized the need for additional comprehensive comparative studies to fully understand the differences in effectiveness.
The retrospective cohort study analyzed over two hundred thousand medical records from the Swedish National Patient Registry, collected between 2006 and 2023. The study included participants aged 16 to 64 who had been diagnosed with alcohol use disorder. Over 6,000 participants were using GLP-1 agonists, with the majority taking semaglutide, and smaller proportions using liraglutide, dulaglutide, and exenatide. With a median follow-up of approximately 9 years, the researchers found that semaglutide and liraglutide significantly reduced the risk of hospitalization due to alcohol use disorder by 36% and 28%, respectively. Furthermore, the study indicated that these GLP-1 agonists were more effective than specialized medications such as naltrexone, disulfiram, and acamprosate. However, due to the study's design, the researchers emphasized the need for additional comprehensive comparative studies to fully understand the differences in effectiveness.